Table 4.
Second-line therapies indicating castration-resistant prostate cancer (N = 2,234).
| Therapy | n | % |
|---|---|---|
| Docetaxel | 1,697 | 76.0 |
| Abiraterone acetate | 215 | 9.6 |
| Sipuleucel-T | 191 | 8.5 |
| Mitoxantrone | 86 | 3.8 |
| Enzalutamide | 30 | 1.3 |
| Cabazitaxel | 15 | 0.7 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.